LIGAND PHARMACEUTICALS INCORPORATED (LGND) Net margin 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) net profit margin by fiscal year — reported net income divided by reported revenue.
46.4%FY2025 · since FY2016: -1.5% → 46.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 46.4% | +48.8 pp |
| FY2024 | -2.4% | -42.1 pp |
| FY2023 | 39.7% | +56.7 pp |
| FY2022 | -17.0% | -40.7 pp |
| FY2021 | 23.7% | +25.5 pp |
| FY2020 | -1.8% | -525.0 pp |
| FY2019 | 523.2% | +466.2 pp |
| FY2018 | 57.0% | +48.1 pp |
| FY2017 | 8.9% | +10.4 pp |
| FY2016 | -1.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating marginLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →